keyword
MENU ▼
Read by QxMD icon Read
search

Cachexia-anorexia cancer

keyword
https://www.readbyqxmd.com/read/28751550/novel-targeted-therapies-for-cancer-cachexia
#1
REVIEW
Josep M Argilés, Francisco Javier López-Soriano, Britta Stemmler, Sílvia Busquets
Anorexia and metabolic alterations are the main components of the cachectic syndrome. Glucose intolerance, fat depletion, muscle protein catabolism and other alterations are involved in the development of cancer cachexia, a multi-organ syndrome. Nutritional approach strategies are not satisfactory in reversing the cachectic syndrome. The aim of the present review is to deal with the recent therapeutic targeted approaches that have been designed to fight and counteract wasting in cancer patients. Indeed, some promising targeted therapeutic approaches include ghrelin agonists, selective androgen receptor agonists, β-blockers and antimyostatin peptides...
July 27, 2017: Biochemical Journal
https://www.readbyqxmd.com/read/28708669/the-role-of-hypothalamic-inflammation-the-hypothalamic-pituitary-adrenal-axis-and-serotonin-in-the-cancer-anorexia-cachexia-syndrome
#2
Klaske van Norren, Jvalini T Dwarkasing, Renger F Witkamp
PURPOSE OF REVIEW: In cancer patients, the development of cachexia (muscle wasting) is frequently aggravated by anorexia (loss of appetite). Their concurrence is often referred to as anorexia-cachexia syndrome. This review focusses on the recent evidence underlining hypothalamic inflammation as key driver of these processes. Special attention is given to the involvement of hypothalamic serotonin. RECENT FINDINGS: The anorexia-cachexia syndrome is directly associated with higher mortality in cancer patients...
July 13, 2017: Current Opinion in Clinical Nutrition and Metabolic Care
https://www.readbyqxmd.com/read/28691536/mabp1-for-the-treatment-of-colorectal-cancer
#3
Geraldine O'Sullivan Coyne, Mauricio Burotto
Inflammation is an established process in colorectal cancer development and a hallmark of progression, and pro-inflammatory cytokines have been implicated in the morbidity and functional compromise associated with malignancy. MABp1, described as a first-in-class true human antibody against interleukin-1α, has undergone clinical trial evaluation in a number of indications, recently completing late phase clinical trial testing under Fast Track designation for cancer anorexia-cachexia syndrome in colorectal cancer patients...
July 10, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28627024/the-applicability-of-a-weight-loss-grading-system-in-cancer-cachexia-a-longitudinal-analysis
#4
Ola Magne Vagnildhaug, David Blum, Andrew Wilcock, Peter Fayers, Florian Strasser, Vickie E Baracos, Marianne J Hjermstad, Stein Kaasa, Barry Laird, Tora S Solheim
BACKGROUND: A body mass index (BMI) adjusted weight loss grading system (WLGS) is related to survival in patients with cancer. The aim of this study was to examine the applicability of the WLGS by confirming its prognostic validity, evaluating its relationship to cachexia domains, and exploring its ability to predict cachexia progression. METHODS: An international, prospective observational study of patients with incurable cancer was conducted. For each patient, weight loss grade was scored 0-4...
June 18, 2017: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/28621564/the-emerging-role-of-anamorelin-hydrochloride-in-the-management-of-patients-with-cancer-anorexia-cachexia
#5
David C Currow, Richard Je Skipworth
Cancer cachexia affects many patients with advanced cancer. This multifactorial syndrome, which involves loss of muscle mass and body weight, profoundly affects patients' physical functioning and quality of life. Pharmacologic interventions that target weight loss and also improve patient-reported measures are required. Anamorelin hydrochloride is an oral ghrelin receptor agonist for the treatment of cancer anorexia-cachexia that stimulates release of growth hormone and insulin-like growth factor 1, and improves food intake and body weight...
June 16, 2017: Future Oncology
https://www.readbyqxmd.com/read/28614627/a-randomized-phase-ii-feasibility-trial-of-a-multimodal-intervention-for-the-management-of-cachexia-in-lung-and-pancreatic-cancer
#6
Tora S Solheim, Barry J A Laird, Trude Rakel Balstad, Guro B Stene, Asta Bye, Neil Johns, Caroline H Pettersen, Marie Fallon, Peter Fayers, Kenneth Fearon, Stein Kaasa
BACKGROUND: Cancer cachexia is a syndrome of weight loss (including muscle and fat), anorexia, and decreased physical function. It has been suggested that the optimal treatment for cachexia should be a multimodal intervention. The primary aim of this study was to examine the feasibility and safety of a multimodal intervention (n-3 polyunsaturated fatty acid nutritional supplements, exercise, and anti-inflammatory medication: celecoxib) for cancer cachexia in patients with incurable lung or pancreatic cancer, undergoing chemotherapy...
June 14, 2017: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/28579820/cannabis-and-intractable-chronic-pain-an-explorative-retrospective-analysis-of-italian-cohort-of-614-patients
#7
Guido Fanelli, Giuliano De Carolis, Claudio Leonardi, Adele Longobardi, Ennio Sarli, Massimo Allegri, Michael E Schatman
BACKGROUND: Despite growing interest in the therapeutic use of cannabis to manage chronic pain, only limited data that address these issues are available. In recent years, a number of nations have introduced specific laws to allow patients to use cannabis preparations to treat a variety of medical conditions. In 2015, the Italian government authorized the use of cannabis to treat several diseases, including chronic pain generally, spasticity in multiple sclerosis, cachexia and anorexia among AIDS and cancer patients, glaucoma, Tourette syndrome, and certain types of epilepsy...
2017: Journal of Pain Research
https://www.readbyqxmd.com/read/28573637/clinical-significance-of-androgen-secretion-disorders-in-men-with-a-malignancy
#8
REVIEW
Pawel J Wiechno, Grazyna M Poniatowska, Wojciech Michalski, Jakub Kucharz, Malgorzata Sadowska, Joanna Jonska-Gmyrek, Karol Nietupski, Joanna Rzymowska, Tomasz Demkow
Cancer and its treatment can lead in men to testosterone deficiency, accompanied by somatic and mental symptoms. Germ cell tumours and their treatment may disturb the pituitary-gonadal axis, hence leading to significant clinical abnormalities. In some prostate cancer patients, castration, temporary or permanent, is a desired therapeutic condition. Yet, it is burdened with various side effects of complex intensity and significance. Last but not least, patients in the terminal stage of a malignancy present with low testosterone concentrations as a part of anorexia-cachexia syndrome...
July 2017: Medical Oncology
https://www.readbyqxmd.com/read/28529141/z-505-hydrochloride-an-orally-active-ghrelin-agonist-attenuates-the-progression-of-cancer-cachexia-via-anabolic-hormones-in-colon-26-tumor-bearing-mice
#9
Makoto Yoshimura, Yoshihiro Shiomi, Yuta Ohira, Mineo Takei, Takao Tanaka
Cancer cachexia is a progressive wasting syndrome characterized by anorexia and weight loss, specifically muscle wasting and fat depletion. There is no therapeutic agent for treatment of this syndrome. We investigated the anti-cachexia effects of Z-505 hydrochloride (Z-505), a new oral growth hormone secretagogue receptor 1a (GHSR1a) agonist, using a mouse model of cancer cachexia. We performed a calcium flux assay in Chinese hamster ovary (CHO-K1) cells stably expressing human GHSR1a to quantify the agonistic activity of Z-505...
May 18, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28475119/oral-treatment-with-the-ghrelin-receptor-agonist-hm01-attenuates-cachexia-in-mice-bearing-colon-26-c26-tumors
#10
Fabienne O Villars, Claudio Pietra, Claudio Giuliano, Thomas A Lutz, Thomas Riediger
The gastrointestinal hormone ghrelin reduces energy expenditure and stimulates food intake. Ghrelin analogs are a possible treatment against cancer anorexia-cachexia syndrome (CACS). This study aimed to investigate whether oral treatment with the non-peptidergic ghrelin receptor agonist HM01 counteracts CACS in colon-26 (C26) tumor-bearing mice. The C26 tumor model is characterized by pronounced body weight (BW) loss and muscle wasting in the absence of severe anorexia. We analyzed the time course of BW loss, body composition, muscle mass, bone mineral density, and the cytokines interleukin-6 (IL-6) and macrophage-inhibitory cytokine-1 (MIC-1)...
May 5, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28471824/early-detection-of-sporadic-pancreatic-cancer-time-for-change
#11
Přemysl Frič, Aleksi Šedo, Jan Škrha, Petr Bušek, Martin Laclav, Pavel Škrha, Miroslav Zavoral
Sporadic pancreatic cancer amounts to ∼90% of all pancreatic cancers. It is a gloomy depressive disease and the most recalcitrant malignancy, with a very low 5-year survival (3-6%). At present, diagnostic methods are commonly applied, as used half a century ago, after the appearance of local and systemic symptoms (abdominal and back pain, cholestasis, painless jaundice, fatigue, anorexia, weight loss, anemia, peripheral phlebitis, and cachexia). Unfortunately, these symptoms are harbingers of an advanced disease...
August 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28469924/anorexia-cachexia-syndrome-like-hypothalamic-neuroendocrine-dysfunction-in-a-patient-with-a-papillary-craniopharyngioma
#12
Lourdes Balcázar-Hernández, Guadalupe Vargas-Ortega, Yelitza Valverde-García, Victoria Mendoza-Zubieta, Baldomero González-Virla
The craniopharyngiomas are solid cystic suprasellar tumors that can present extension to adjacent structures, conditioning pituitary and hypothalamic dysfunction. Within hypothalamic neuroendocrine dysfunction, we can find obesity, behavioral changes, disturbed circadian rhythm and sleep irregularities, imbalances in the regulation of body temperature, thirst, heart rate and/or blood pressure and alterations in dietary intake (like anorexia). We present a rare case of anorexia-cachexia syndrome like a manifestation of neuroendocrine dysfunction in a patient with a papillary craniopharyngioma...
2017: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/28447434/the-influence-of-different-muscle-mass-measurements-on-the-diagnosis-of-cancer-cachexia
#13
Susanne Blauwhoff-Buskermolen, Jacqueline A E Langius, Annemarie Becker, Henk M W Verheul, Marian A E de van der Schueren
BACKGROUND: Progressive loss of muscle mass is a major characteristic of cancer cachexia. Consensus definitions for cachexia provide different options to measure muscle mass. This study describes the effect of different methods to determine muscle mass on the diagnosis of cancer cachexia. In addition, the association of cachexia with other features of cachexia, quality of life, and survival was explored. METHODS: Prior to chemotherapy, cachexia was assessed by weight loss, body mass index, and muscle mass measurements, the latter by mid-upper arm muscle area (MUAMA), computed tomography (CT) scans, and bio-electrical impedance analysis (BIA)...
April 26, 2017: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/28398233/therapeutic-potential-of-targeting-the-ghrelin-pathway
#14
REVIEW
Gustav Colldén, Matthias H Tschöp, Timo D Müller
Ghrelin was discovered in 1999 as the endogenous ligand of the growth-hormone secretagogue receptor 1a (GHSR1a). Since then, ghrelin has been found to exert a plethora of physiological effects that go far beyond its initial characterization as a growth hormone (GH) secretagogue. Among the numerous well-established effects of ghrelin are the stimulation of appetite and lipid accumulation, the modulation of immunity and inflammation, the stimulation of gastric motility, the improvement of cardiac performance, the modulation of stress, anxiety, taste sensation and reward-seeking behavior, as well as the regulation of glucose metabolism and thermogenesis...
April 11, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28390870/insulin-not-glutamine-dipeptide-reduces-lipases-expression-and-prevents-fat-wasting-and-weight-loss-in-walker-256-tumor-bearing-rats
#15
Hely de Morais, Flaviane de Fatima Silva, Francemilson Goulart da Silva, Milene Ortiz Silva, Maria Fernanda Rodrigues Graciano, Maria Isabel Lovo Martins, Ângelo Rafael Carpinelli, Tânia Longo Mazucco, Roberto Barbosa Bazotte, Helenir Medri de Souza
Cachexia is the main cause of mortality in advanced cancer patients. We investigated the effects of insulin (INS) and glutamine dipeptide (GDP), isolated or associated, on cachexia and metabolic changes induced by Walker 256 tumor in rats. INS (NPH, 40 UI/kg, sc) or GDP (1.5g/kg, oral gavage) was once-daily administered during 11 days after tumor cell inoculation. GDP, INS or INS+GDP treatments did not influence the tumor growth. However, INS and INS+GDP prevented retroperitoneal fat wasting and body weight loss of tumor-bearing rats...
April 6, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28315777/appetite-disorders-in-cancer-patients-impact-on-nutritional-status-and-quality-of-life
#16
David E Barajas Galindo, Alfonso Vidal-Casariego, Alicia Calleja-Fernández, Ana Hernández-Moreno, Begoña Pintor de la Maza, Manuela Pedraza-Lorenzo, María Asunción Rodríguez-García, Dalia María Ávila-Turcios, Miran Alejo-Ramos, Rocío Villar-Taibo, Ana Urioste-Fondo, Isidoro Cano-Rodríguez, María D Ballesteros-Pomar
Cancer patients are at high risk of malnutrition due to several symptoms such as lack of appetite. The aim of this study was to determine the prevalence of different appetite disorders in cancer patients and their influence on dietary intake, nutritional status, and quality of life. We conducted a cross-sectional study of cancer patients at risk of malnutrition. Nutritional status was studied using Subjective Global Assessment, anthropometry, and grip strength. Dietary intake was evaluated with a 24-h recall, and patients were questioned about the presence of changes in appetite (none, anorexia, early satiety, or both)...
March 16, 2017: Appetite
https://www.readbyqxmd.com/read/28298897/plasma-ghrelin-levels-are-associated-with-anorexia-but-not-cachexia-in-patients-with-nsclc
#17
Susanne Blauwhoff-Buskermolen, Jacqueline A E Langius, Annemieke C Heijboer, Annemarie Becker, Marian A E de van der Schueren, Henk M W Verheul
Background and Aims: The ghrelin receptor is one of the new therapeutic targets in the cancer anorexia-cachexia syndrome. Previous studies revealed that plasma ghrelin levels were high in patients with anorexia nervosa and low in obese subjects. We studied to what extent ghrelin levels are related with anorexia and cachexia in patients with cancer. Materials and Methods: Fasted ghrelin levels were determined as well as anorexia and cachexia in patients with stage III/IV non-small cell lung cancer before chemotherapy...
2017: Frontiers in Physiology
https://www.readbyqxmd.com/read/28261113/validation-of-the-cachexia-score-casco-staging-cancer-patients-the-use-of-minicasco-as-a-simplified-tool
#18
Josep M Argilés, Angelica Betancourt, Joan Guàrdia-Olmos, Maribel Peró-Cebollero, Francisco J López-Soriano, Clelia Madeddu, Roberto Serpe, Sílvia Busquets
The CAchexia SCOre (CASCO) was described as a tool for the staging of cachectic cancer patients. The aim of this study is to show the metric properties of CASCO in order to classify cachectic cancer patients into three different groups, which are associated with a numerical scoring. The final aim was to clinically validate CASCO for its use in the classification of cachectic cancer patients in clinical practice. We carried out a case -control study that enrolled prospectively 186 cancer patients and 95 age-matched controls...
2017: Frontiers in Physiology
https://www.readbyqxmd.com/read/28259044/neuroimmune-mechanisms-of-behavioral-alterations-in-a-syngeneic-murine-model-of-human-papilloma-virus-related-head-and-neck-cancer
#19
Elisabeth G Vichaya, Daniel W Vermeer, Diana L Christian, Jessica M Molkentine, Kathy A Mason, John H Lee, Robert Dantzer
Patients with cancer often experience a high symptom burden prior to the start of treatment. As disease- and treatment-related neurotoxicities appear to be additive, targeting disease-related symptoms may attenuate overall symptom burden for cancer patients and improve the tolerability of treatment. It has been hypothesized that disease-related symptoms are a consequence of tumor-induced inflammation. We tested this hypothesis using a syngeneic heterotopic murine model of human papilloma virus (HPV)-related head and neck cancer...
May 2017: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/28249026/development-of-ghrelin-resistance-in-a-cancer-cachexia-rat-model-using-human-gastric-cancer-derived-85as2-cells-and-the-palliative-effects-of-the-kampo-medicine-rikkunshito-on-the-model
#20
Kiyoshi Terawaki, Yohei Kashiwase, Yumi Sawada, Hirofumi Hashimoto, Mitsuhiro Yoshimura, Katsuya Ohbuchi, Yuka Sudo, Masami Suzuki, Kanako Miyano, Seiji Shiraishi, Yoshikazu Higami, Kazuyoshi Yanagihara, Tomohisa Hattori, Yoshio Kase, Yoichi Ueta, Yasuhito Uezono
Cancer cachexia (CC) is a multifactorial disease characterized by decreased food intake and loss of body weight due to reduced musculature with or without loss of fat mass. Patients with gastric cancer have a high incidence of cachexia. We previously established a novel CC rat model induced by human gastric cancer-derived 85As2 cells in order to examine the pathophysiology of CC and identify potential therapeutics. In patients with CC, anorexia is often observed, despite elevation of ghrelin, suggesting that ghrelin resistance may develop in these patients...
2017: PloS One
keyword
keyword
103177
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"